- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07361406
SweetSpot - Het effect van niet-voedzame zoetstoffen op de gezondheid
SweetSpot - Het effect van niet-voedzame zoetstoffen op de glucoseregulatie, darmmicrobioom en darmhormoonsecretie bij gezonde volwassenen: een volledig gecontroleerde cross-over interventiestudie
The aim of the study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Sugar intake has increased over the years, simultaneously with the prevalence of overweight and obesity. To decrease sugar intake, consumption of non-nutritive sweeteners (NNS) has increased and opinions on its use remain divided. A fully controlled dietary intervention using a NNS mixture and dose that is similar to real-life intake, is therefore necessary to advance our understanding of the potential effects of NNS on glucose regulation, gut microbiome, and gut hormone secretion under real-life conditions.
The aim of this study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.
To do this, a single blind, fully controlled dietary intervention with a cross-over design will be performed. The study will consist of 2x8 weeks of intervention, with a washout of > 6 weeks in between. The study population will be 60 healthy adults aged 45-79, with a BMI between 20-35 kg/m2.
The study will consist of a fully controlled diet of two 8-week intervention periods (2 weeks run-in + 6 weeks intervention). The diets differ in the presence of non-nutritive sweeteners (NNS): NNS-diet versus non-NNS diet, where additional NNS are added to the NNS-diet.
The primary outcome measure will be the within person difference in blood glucose incremental area under the curve following a 75 g glucose tolerance test between the NNS diet and the non-NNS diet. Secondary outcome measures are the effect of NNS on Matsuda index, insulin response, blood lipid profile, and gut hormone secretion will be determined. The effect of NNS on small- and large intestinal microbiome will be investigated by a change in composition, functionality, and short chain fatty acid content. The effect of NNS on sweet taste sensitivity, preference, and liking will be investigated, as well as the excretion of NNS in urine and saliva.
The total time invested by participants is around 85 hours. Participants are restricted for 16 weeks in their eating habits, since they follow a fully controlled diet prepared by the research facility. Participants will visit the research facility in total 38 times. In total, ~ 603 mL of blood will be drawn by experienced nurses over the entire RCT (>6 month period). During DEXA scans, participants will receive a total of about 0.006 mSv of radiation.
Invasive measurements that participants can experience as burden are collection of faecal and urine samples, and finding back the Simba capsules in the stool. Non-invasive measurements for participants are wearing the CGM, wearing the ActiGraph, consuming the blue cakes, and performing sensory tests.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Gelderland
-
Wageningen, Gelderland, Nederland, 6708WG
- Wageningen University & Research
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 45-79 years;
- BMI of 20-35 kg/m2;
- Having veins suitable for placement of a venflon catheter.
Exclusion Criteria:
- Diseases or prior surgeries affecting the stomach, liver, kidneys or intestines (allowed i.e. appendectomy);
- Cardiovascular diseases (e.g. heart failure) or cancer (e.g. non-invasive skin cancer allowed);
- Diagnosed with type 1 or type 2 diabetes;
- Drug treated thyroid diseases (well substituted hypothyroidism is allowed for inclusion);
- HbA1c level >6.5% (>48 mmol/mol), as measured during the screening visit;
- Anaemia defined as Hb concentrations <8.5 mmol/L for men and <7.5 mmol/L for women via finger prick;
- Regular use of/receiving medication interfering with research outcomes (as judged by research physician), such as use of glucose lowering drugs, insulin, or use of medication that impacts the gastro-intestinal system;
- Use of antibiotics over the last 3 months before study start;
- Donated blood within 2 months prior to the screening;
- Food allergies, intolerances (including lactose/gluten intolerance) for products used in the study design and/or dietary restrictions interfering with the study (including special diets and eating disorders);
- Followed a diet that can interfere with the study outcomes within 1 month prior to the screening (e.g. ketogenic, sugar free, carbohydrate free);
- Not willing to eat all products in the study diet, including eggs and dairy. Vegetarian is possible;
- Not willing to consume non-nutritive sweeteners;
- Not willing to quit the use of supplements that can interfere with the study outcomes (e.g. pre- or probiotics).
- Intention to change the intensity of exercise during the study period or planning to join a intensive sport event (e.g. marathon or triathlon);
- Intention to lose or gain weight;
- Working night shifts regularly;
- Smoking regularly
- Use of soft and/or hard drugs (cannabis included);
- Abuse of alcohol (defined as >14 glasses (women) or >21 glasses (men) of alcoholic beverages per week);
- Being pregnant or lactating or planning to become pregnant;
- Inability to understand study information and/or communicate with staff;
- Participation in another study that involves an intervention within two months prior to the intervention;
- Working or doing a thesis/internship at the division of Human Nutrition & Health, or the Food, Health & Consumer Research group of Wageningen Food & Biobased Research.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: NNS / no-NNS
In this arm, participants will first receive the NNS diet, and the no-NNS diet in the second study period. |
Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia). Fully controlled diet without any non-nutritive sweeteners added. |
|
Ander: No-NNS / NNS
In this arm, participants will first receive the no-NNS diet, and the NNS diet in the second study period. |
Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia). Fully controlled diet without any non-nutritive sweeteners added. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Difference in change in 2h iAUC glucose after 6 weeks between the intervention and the control.
Tijdsspanne: Week 2 and week 8 in both intervention periods (4 times in total)
|
The primary outcome measure is the difference in change in iAUC of blood glucose levels following a 2-hour oral glucose tolerance test (OGTT) after six weeks between the intervention period and the control period. |
Week 2 and week 8 in both intervention periods (4 times in total)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Matsuda index
Tijdsspanne: Week 2 and week 8 in both intervention periods (4 times in total)
|
Matsuda index after an OGTT |
Week 2 and week 8 in both intervention periods (4 times in total)
|
|
Fasting blood glucose
Tijdsspanne: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Fasting blood glucose |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Fasting blood insulin
Tijdsspanne: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Fasting blood insulin |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Postprandial insulin response
Tijdsspanne: Week 2 and 8 in both intervention periods (4 times in total).
|
2-hour iAUC blood insulin during OGTT |
Week 2 and 8 in both intervention periods (4 times in total).
|
|
Postprandial glucose response after a breakfast
Tijdsspanne: Week 7 in both study periods (2 times in total)
|
Postprandial blood glucose responses (PPGR) following specific meals measured by CGM. |
Week 7 in both study periods (2 times in total)
|
|
Blood lipid profile
Tijdsspanne: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
All circulating blood lipids, including all cholesterol types, triglycerides, and free fatty acids (FFAs). |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Gut microbiota composition
Tijdsspanne: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
Microbiota composition in faeces |
Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
|
Gut microbiota function
Tijdsspanne: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
Microbiota functionality measured in faeces |
Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
|
Microbial metabolites
Tijdsspanne: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
Microbial metabolites measured in faeces |
Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
|
|
Small intestinal microbiota composition
Tijdsspanne: Week 7 of both intervention periods (2 times in total).
|
Microbiota composition of the small intestine measured with Simba Capsules |
Week 7 of both intervention periods (2 times in total).
|
|
Gastro-intestinal transit time
Tijdsspanne: Baseline & week 7 of both intervention periods (3 times in total).
|
Gastro-intestinal transit time measured with blue muffins. |
Baseline & week 7 of both intervention periods (3 times in total).
|
|
Oral microbiome composition & function
Tijdsspanne: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Oral microbiome composition & function measured in saliva |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Postprandial GLP-1 secretion
Tijdsspanne: Week 2 and 8 of both intervention periods (4 times in total).
|
3-hour AUC of GLP-1 during an OGTT. |
Week 2 and 8 of both intervention periods (4 times in total).
|
|
Postprandial GIP secretion
Tijdsspanne: Week 2 and 8 of both intervention periods (4 times in total).
|
3-hour AUC of GIP during an OGTT. |
Week 2 and 8 of both intervention periods (4 times in total).
|
|
Sweetness-liker phenotype
Tijdsspanne: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Sweetness-liker phenotype, with the sweetness liker test. |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Sweetness preference & liking
Tijdsspanne: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Sweetness preference & liking measured on a rank-rating scale. Preference will be determined using the categorical values from the rank-rating scale (1-5), and liking will be determined using the continuous values from the rank-rating scale (0-100). |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Sweet taste sensitivity
Tijdsspanne: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Sweet taste sensitivity measured on a 100mm Visual Analogue Scale. A higher score for all solutions indicates a higher sweet taste sensitivity. |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
|
Excretion of NNS in urine
Tijdsspanne: Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).
|
Excretion of NNS in urine |
Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).
|
|
Excretion of NNS in saliva
Tijdsspanne: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Excretion of NNS in saliva |
Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Anthropometrics
Tijdsspanne: Baseline
|
Measured as weight (kg), height (m), waist circumference (cm), and hip circumference (cm). Weight and height will be combined to report BMI in kg/m^2. |
Baseline
|
|
Body composition
Tijdsspanne: Baseline & week 8 of both intervention periods (3 times in total).
|
Body composition as measured by DEXA (Dual Energy X-ray Absorptiometry). |
Baseline & week 8 of both intervention periods (3 times in total).
|
|
Habitual food intake
Tijdsspanne: Baseline
|
Habitual dietary intake assessment with a food frequency questionnaire (FFQ). |
Baseline
|
|
Physical activity level
Tijdsspanne: Baseline.
|
Physical activity level by the Short Questionnaire to Assess Health-enhancing physical activity (SQUASH). |
Baseline.
|
|
Habitual NNS consumption
Tijdsspanne: Baseline
|
Habitual NNS consumption by questionnaire |
Baseline
|
|
Gastro-intestinal symptoms
Tijdsspanne: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
Gastro-intestinal symptoms by GSRS questionnaire. |
Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
|
Satiety
Tijdsspanne: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
Satiety questionnaire, adapted from the Control of Eating Questionnaire. |
Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
|
|
Genetic variation
Tijdsspanne: Baseline
|
Single Nucleotide Polymorphisms (SNPs) in genes relevant collected using buffycoat. |
Baseline
|
|
Taste function
Tijdsspanne: Baseline
|
Measure the ability to recognize the basic tastes in different concentrations, assessed with validated Taste Strips. |
Baseline
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NL010297
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .